Sara Dellasala
Overview
Explore the profile of Sara Dellasala including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
467
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Haddad F, Sasaki K, Senapati J, Hu S, Dellasala S, Issa G, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Nov;
PMID: 39592322
Introduction: The discontinuation of third-generation BCR::ABL1 tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia in chronic phase (CML-CP) is not well understood. We aim to evaluate treatment-free remission...
2.
Haddad F, Sasaki K, Nasr L, Short N, Kadia T, Dellasala S, et al.
Cancer
. 2024 May;
130(19):3344-3352.
PMID: 38804723
Background: Ponatinib is a third-generation BCR::ABL1 tyrosine kinase inhibitor (TKI) with robust activity in Philadelphia chromosome-positive leukemias. Herein, we report the long-term follow-up of the phase 2 trial of ponatinib...
3.
Jabbour E, Sasaki K, Haddad F, Issa G, Garcia-Manero G, Kadia T, et al.
Am J Hematol
. 2023 Jan;
98(4):658-665.
PMID: 36683287
The BCR::ABL1 tyrosine kinase inhibitors (TKIs) have improved the outcomes of patients with chronic myeloid leukemia (CML). After failing second-generation TKI (2G-TKI), the optimal third-line therapy in chronic phase CML...
4.
Jabbour E, Sasaki K, Haddad F, Issa G, Skinner J, Dellasala S, et al.
Am J Hematol
. 2022 Sep;
97(11):1413-1418.
PMID: 36054032
Low-dose dasatinib is safe and effective in patients with chronic myeloid leukemia in chronic phase (CML-CP). No randomized trials have compared the outcome with standard-dose dasatinib. This study aims to...
5.
Ohanian M, Kantarjian H, Shoukier M, Dellasala S, Musaelyan A, Nogueras Gonzalez G, et al.
Am J Hematol
. 2020 Jun;
95(10):1127-1134.
PMID: 32557828
We aimed to describe the impact of time to response on the outcomes of 75 patients with accelerated-phase chronic myeloid leukemia (CML-AP) at diagnosis. Patients had at least 1 feature...
6.
Masarova L, Cortes J, Patel K, OBrien S, Nogueras-Gonzalez G, Konopleva M, et al.
Cancer
. 2020 Jan;
126(7):1448-1459.
PMID: 31999850
Background: Nilotinib is a potent, second-generation inhibitor of BCR-ABL1 tyrosine kinase and has been approved as frontline and salvage therapy for patients with chronic-phase chronic myeloid leukemia (CP-CML). Methods: In...
7.
Maiti A, Cortes J, Patel K, Masarova L, Borthakur G, Ravandi F, et al.
Cancer
. 2020 Jan;
126(7):1502-1511.
PMID: 31999839
Background: Dasatinib is a second-generation tyrosine kinase inhibitor that, when used as frontline therapy, produces more and faster cytogenetic and molecular responses compared with imatinib. The authors report the long-term...
8.
Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M, et al.
Cancer
. 2019 Sep;
126(1):67-75.
PMID: 31553487
Background: Dasatinib, a potent Bcr-Abl tyrosine kinase inhibitor, is approved for the treatment of chronic-phase chronic myeloid leukemia (CML-CP) in the frontline and salvage settings. Notable side effects include pleural...
9.
Naqvi K, Cortes J, Luthra R, OBrien S, Wierda W, Borthakur G, et al.
Int J Hematol
. 2018 Feb;
107(6):689-695.
PMID: 29464484
Kinase domain (KD) mutations of ABL1 represent the most common resistance mechanism to tyrosine kinase inhibitors (TKI) in CML. Besides T315I, mutations in codon 255 are highly resistant mutations in...
10.
Boddu P, Shah A, Borthakur G, Verstovsek S, Garcia-Manero G, Daver N, et al.
Leuk Lymphoma
. 2017 Oct;
59(6):1312-1322.
PMID: 28972430
Ponatinib is a pan-tyrosine kinase inhibitor (TKI) with efficacy in multirefractory CML patients who have failed other TKIs. Despite excellent response rates, resistance or intolerance may develop. We conducted a...